摘要
目的探讨肿瘤坏死因子-α(TNF-α)在高糖、高脂饮食诱导的2型糖尿病大鼠肝脏的表达以及罗格列酮对2型糖尿病合并脂肪肝的治疗作用。方法通过高糖、高脂饮食结合小剂量链脲佐菌素的方法建立2型糖尿病大鼠合并脂肪肝的动物模型,再给予罗格列酮进行干预治疗。4周、8周末测量大鼠血糖、血脂和胰岛素水平,18周末测各组大鼠血糖、血清血脂、胰岛素、丙氨碱转氨酶、TNF-α和瘦素水平,并检测TNF-α在肝脏的蛋白表达水平。结果TNF-α在糖尿病组大鼠肝脏的表达明显增加,罗格列酮可以显著降低糖尿病大鼠血糖、血脂和肝脏的脂肪含量,改善胰岛素抵抗状态,降低TNF-α在肝脏的表达水平。结论罗格列酮对合并脂肪肝的糖尿病大鼠具有一定的治疗作用。
Objective To investigate the pathogenesis of the fatty liver and the treatment of the type 2 diabetes mellitus complicated with fatty liver by using rosiglitazone. Methods The rat model of type 2 diabetes mellitus complicated with fatty liver was set up by feeding high-glucose and high-fat diet and by injecting STZ into the peritoneal cavity of rat. Then, the rats were given an intervention with rosiglitazone. At the end of 4 weeks and 8 weeks, the fasting blood glucose, the levels of fasting serum insulin,TG andTC were measured.At the end of 18 weeks the fasting blood glucose,the levels of fasting serum insulin,ALT, TNF-α and the levels of leptin in all the groups were measured and the expression of TNF-α in the liver was detected. Results The expression of TNF-α in the liver of the rats of the type 2 diabetes mellitus obviously increased. Rosiglitazone could obviously reduce the blood glucose,TG,TC and the fatty levels of the liver, improve the state of the insulin resistance and reduce the expressive levels of the TNF-α in the liver. Conclusions Rosiglitazone is effective in treating rats with type 2 diabetes mellitus complicated with fatty liver.
出处
《河北医药》
CAS
2007年第1期33-35,共3页
Hebei Medical Journal
基金
河北省卫生厅基金资助项目(编号:03041)
关键词
2型糖尿病
非酒精性脂肪肝
胰岛素抵抗
肿瘤坏死因子-Α
罗格列酮
type 2 diabetes mellitus
nonalcoholic fatty liver disease
insulin resistance
tumor necrosis factor-alpha
rosiglitazone
